今回の文献では慢性歯周炎を合併した
コントロール良好な2型糖尿病患者に対する
SRPと0.5%クラリスロマイシンゲル（CLM）の
局所併用療法の有効性を検証しています。
インドにおいて
慢性歯周炎を合併したコントロール良好な
二型糖尿病患者63名を
テスト群とコントロール郡に分けています。
テスト群：SRPとCLMの併用32名
コントロール群：SRPとプラセボゲルの併用31名
主要評価項目はPPDとCALと
歯肉出血インデックスです。
Several epidemiologic studies have identified a greater incidence of periodontitis in patients with type 2 diabetes. Recent developments suggest that local delivery of antimicrobials into periodontal pockets improve periodontal health. The present study was designed to investigate the adjunctive effects of subgingivally delivered clarithromycin (CLM) (0.5% concentration) as an adjunct to scaling and root planing for treating chronic periodontitis in patients with well-controlled type 2 diabetes.
Sixty-three patients were categorized into two treatment groups: Group 1, scaling and root planing (SRP) plus 0.5% CLM; Group 2, SRP plus placebo gel. Clinical parameters were recorded at baseline, 1, 2, and 3 months; which included gingival index (GI), sulcus bleeding index (SBI), plaque index (PI), probing depth (PD), and periodontal attachment level (PAL).
Both therapies resulted in significant improvements. Using a subject-based analysis, patients in Group 1 treated with SRP + CLM showed enhanced reductions in PI, GI, SBI, and PD, and gains in PAL (P < 0.001) over a period of 6 months as compared to Group 2.
Although both treatment strategies seemed to benefit the patients, the adjunctive use of 0.5% CLM as a controlled drug delivery system enhanced the clinical outcome.
結果は、両群とも治療後6か月まで
臨床的パラメーターは経時的に有意な改善が認められた。
PPD,CAL,GBIは、テスト群でコントロール郡に比較して
より有意な減少効果を示した。
結論は、CLMの局所併用療法は
慢性歯周炎を合併した2型糖尿病患者に
有効であると考えられる
ということです。
引用文献
Pavan Bajaj,A R Pradeep,Esha Agarwal,Minal Kumari and Savitha B. Naik
Locally delivered 0.5% clarithromycin, as an adjunct to nonsurgical treatment in chronic periodontitis with well-controlled type 2 diabetes: a randomized controlled clinical trial
Journal of Investigative and Clinical Dentistry Volume 3, Issue 4, pages 276–283, November 2012